// App-Quantinova.ai

EP1087 : SAFETY AND EFFICACY OF MEPOLIZUMAB IN HYPEREOSINOPHILIC SYNDROME: AN OPEN-LABEL EXTENSION STUDY

Researchers

Presenter

  • Florence Roufosse

Principal Investigators

  • Jonathan Steinfeld

  • Gerald J. Gleich

  • Geoffrey Chupp

  • Stanislas Faguer

  • Andreas Reiter

  • Bastian Walz

  • Jane H. Bentley

  • Eric S. Bradford

  • Steven W. Yancey

Medical Centers

  • Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, United States.

  • Department of Nuclear Medicine, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

  • Internal Medicine, University of Utah, Salt Lake City, UT

  • Respiratory Research &amp

  • Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States

  • Département de Néphrologie et Transplantation d'Organes,CHU de Toulouse,Toulouse,France

  • Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom,

  • Department of Hematology and Medical Oncology, University Medical Centre Mannheim, Mannheim, Germany

  • Development,GSK,Collegeville,United States

  • Department of Internal Medicine, Rheumatology and Immunology,University of Tübingen,Kirchheim-Teck,Germany

Locations

  • United States

  • Belgium

  • France

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Hypereosinophilic Syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Pharmacodynamics

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT02836496

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved